
Investing.com——伊利利公司(Eli Lilly)股价在周四盘前上涨2.8%,因中国药品监管部门批准了该公司的减肥药口服制剂orforglipron。
Investing.com -- Eli Lilly shares gained 2.8% premarket Thursday after China's medicine regulator approved the company's weight-loss pill orforglipron.
该批准使利利在全球第二大医药市场相较于丹麦竞争对手诺和诺德(Novo Nordisk)拥有优势。orforglipron将在中国与诺和诺德、辉瑞以及本土企业信达生物的每周一次GLP‑1减肥注射剂争夺市场份额。
The approval gives Lilly an advantage over Danish rival Novo Nordisk in the world's second-largest pharmaceutical market. Orforglipron will compete for market share in China with once-weekly GLP-1 weight-loss injections from Novo Nordisk, Pfizer, and local firm Innovent Biologics.
中国国家卫生健康委员会表示,超重或肥胖人群的比例到2030年可能超过65%。
China's National Health Commission has said the rate of overweight or obese people could reach more than 65% by 2030.




诺和诺德和利利均认为,减肥药片能够吸引不愿使用注射剂的患者。
Both Novo Nordisk and Lilly believe weight-loss pills could attract patients reluctant to use injections.

诺和诺德的口服版Wegovy尚未在中国获批。利利是首家提交orforglipron申请的公司。
Novo's oral version of Wegovy has not yet been approved in China. Lilly was first to apply with orforglipron.
此外,里克特(Richter)宣布与利利达成以雌酮(E4)为中心的战略合作。根据协议,利利获得E4在女性健康和心代谢疾病领域的全球开发权,并拥有在美国共同商业化FYLREVY的选项。
Moreover, Richter has announced a strategic partnership with Lilly centered around estetrol (E4). Under the terms of the agreement, Lilly gains global rights to develop E4 combinations in women’s health and cardiometabolic disease, as well as an option to co-commercialize FYLREVY in the US.
作为回报,里克特获得E4供应经济性以及潜在的里程碑付款和版税。
In return, Richter secures E4 supply economics alongside potential milestone payments and royalties.
另外,利利将从库藏中收购约1500万美元的RICHT普通股。
Additionally, Lilly will acquire approximately $15 million of RICHT ordinary shares from treasury.
伊利利股票在中国批准减肥药后上涨。
Eli Lilly stock rises after China approves weight-loss pill